Sentences with phrase «androgen deprivation therapy»

«The risk of cognitive impairment should be considered when deciding whether or not to receive androgen deprivation therapy for prostate cancer,» said Brian Gonzalez, Ph.D., a postdoctoral fellow in the Health Outcomes and Behavior Program at Moffitt.

«A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration - resistant prostate cancer,» said Ronald DePinho, M.D., professor of Cancer Biology.

There have been several studies analyzing this side effect in breast cancer patients, but few have investigated cognitive impairment following androgen deprivation therapy (ADT) for men being treated prostate cancer.

A significant fraction of advanced PCa treated with androgen deprivation therapy experience relentless progression to lethal metastatic castration - resistant prostate cancer (mCRPC).

All had been treated previously with at least one type of androgen deprivation therapy and had rising levels of prostate specific antigen (PSA), a blood marker for prostate cancer, and radiographic evidence their cancers were becoming resistant.

Radiographic progression at study entry while on androgen deprivation therapy (or after bilateral orchiectomy).

Hormone therapies, known as androgen deprivation therapies, help arrest the disease by reducing a patient's androgen levels.

The authors focused on men newly diagnosed with localized (non-metastatic) prostate cancer in 1995 - 2011 and treated with radical prostatectomy, brachytherapy, radiation therapy, or primary androgen deprivation therapy (PADT).

The researchers also reported for the first time a possible genetic link among those individuals who experience cognitive impairment during androgen deprivation therapy.

Long term follow up indicates that men with comorbidity, predominately a prior heart attack, who received androgen deprivation therapy (ADT) died earlier, due to a fatal heart attack.

Hormone - lowering therapy is also called androgen deprivation therapy or androgen suppression therapy.

They found that patients who have a particular version of a gene called GNB3 were 14 times more likely to suffer from cognitive problems following androgen deprivation therapy.

A new study published in The Journal of Urology ® reports that prostate cancer patients treated with androgen deprivation therapy (ADT) experienced changes in mental and emotional well - being during treatment, although there was no meaningful decline in emotional quality of life two years after treatment.

Sexual dysfunction — including but not limited to erectile dysfunction (ED)-- is reported by up to 85 percent of radiation therapy patients during treatment, often due to the concurrent use of androgen deprivation therapy (ADT).

A new Moffitt Cancer Center study indicated that men who are on androgen deprivation therapy have greater odds of experiencing impaired cognitive function.

LIVE BROADCAST 5/11 2 PM EDT - Androgen Deprivation Therapy in Prostate Cancer and Cardiovascular Risk

Researchers at Brigham and Women's Hospital found that a prostate specific antigen (PSA) nadir (the lowest level a PSA drops after treatment) greater than 0.5 ng / mL following radiation and androgen deprivation therapy (anti-hormone therapy), appears to identify men prior to PSA failure who are at high - risk for dying early as a result of treatment failure for their prostate cancer.

Androgen deprivation therapy was not allowed among study participants.

Enzalutamide, which is taken as four pills once per day, is already approved by the Food and Drug Administration (FDA) for men whose disease has not been stopped by other treatments including, surgery, radiation, androgen deprivation therapy and chemotherapy.

The patients initially received androgen deprivation therapy (ADT), aimed at reducing levels of the male hormones that stimulate prostate cancer cells to grow.

Denmeade says the combination of drugs that block testosterone production and receptors, called androgen deprivation therapy, may make prostate cancer more aggressive over time by enabling prostate cancer cells to subvert attempts to block testosterone receptors.

«Androgen deprivation therapy associated with increased risk for fatal heart attack: Long term follow up indicates that men with comorbidity, predominately a prior heart attack, who received androgen deprivation therapy died earlier, due to a fatal heart attack.»

«There has been a groundswell of interest in the idea of reversing resistance to androgen deprivation therapy.

Androgen deprivation therapy (ADT) and radiation therapy (RT) is known to prolong survival in men with unfavorable - risk prostate cancer and is considered a standard of care.

The cells also might react by making fewer receptors, which may make the prostate tumor cells vulnerable once more to androgen deprivation therapy.

Brachytherapy is an extremely efficient and safe radiation oncology modality, and this trial shows that it can have a wider field of applicability than simply in very localised and low risk tumours when combined with other techniques — in this case, androgen deprivation therapy and external bean radiation therapy.»

The research teams, led by Nima Sharifi, M.D., of the Cleveland Clinic Lerner Research Institute, studied the role of the HSD3B1 (1245C) genetic variant in two different prostate cancer patient populations, following androgen deprivation therapy (ADT).

Androgen deprivation therapy is a powerful tool against prostate cancer, and more and more men are opting for the treatment as a growing array of hormone - based therapies become available.

«Androgen deprivation therapy may lead to cognitive impairment in prostate cancer patients.»

In this study, researchers used formal tests to compare the cognitive ability of 58 prostate cancer patients receiving androgen deprivation therapy to 84 prostate cancer patients who did not receive ADT, and to 88 men without cancer.

Androgen deprivation therapy is commonly used to treat prostate cancer, often on an open - ended basis for therapy of advanced prostate cancer.

For more than 60 years, the standard of care for patients with prostate cancer fueled by androgen hormones that has spread to other parts of the body has been androgen deprivation therapy (ADT).

Acceptance of the final manuscript in The New England Journal of Medicine along with confirmatory data from the Medical Research Council trial called STAMPEDE presented at ASCO 2015, provides the requisite peer review publication and evidence of reproducibility that will lead to docetaxel plus androgen deprivation therapy being the standard of care for patients fit for chemotherapy with metastatic hormone sensitive prostate cancer.

Androgen deprivation therapy (ADT) is a common treatment option for patients with advanced stage prostate cancer.

When prostate cancer spreads, androgen deprivation therapy («medical castration») is used to cut off the tumor's energy supply.

In current practice, men newly diagnosed with prostate cancer that has spread widely, and whose cancer depends on male hormones to grow, are started on hormone - blocking medications — androgen deprivation therapy (ADT).

Long - term follow - up of a large phase III study showed that chemohormonal therapy involving docetaxel added to androgen deprivation therapy (ADT) prolongs overall survival (OS) over ADT alone in metastatic hormone - sensitive prostate cancer (mHSPC) patients with high - volume disease.

Common conventional treatment is androgen deprivation therapy (ADT), which drastically reduces testosterone levels resulting in many distressing side effects, such as sexual dysfunction.